TruLaw is currently filing lawsuits on behalf of individuals that took fluoroquinolones (FQs) such as Levaquin, Avelox, Cipro, Noroxin, Floxin, and Factive and experienced an aortic aneurysm or aortic dissection.  In addition, cases where individuals were diagnosed with peripheral neuropathy or are experiencing a “constellation of symptoms” across multiple body parts are also being filed.  These antibiotic lawsuits are being filed against the manufacturers of Levaquin, Avelox, Cipro, Noroxin, Floxin and Factive – these are not lawsuits against doctors.

TruLaw encourages those individuals that believe they were injured by a fluoroquinolone to fill out the Instant Case Evaluation to determine if their diagnosis, side effects or symptoms may be linked to their antibiotic.

TruLaw believes in holding large drug and device companies accountable when they put profits ahead of safety. The outcome of each legal case depends upon many factors and no attorney can guarantee a positive result in any particular case. It is imperative that you research your legal options.

TruLaw is a recognized leader in products liability cases serving, as co-lead counsel for the plaintiffs on the Actos bladder cancer cases that settled in 2015 for $2.4 billion. We encourage you to research TruLaw at our website, read our blogs or join us on our social media feeds. Or, better yet, give us a call.


Antibiotic Manufacturers Did Not Properly Warn of Their Risks


FQs have been used for over 20 years. Over the life-cycle of these drugs, the FDA has required a number of different changes to the labels to warn for adverse events.

Recent studies show a 2-fold increased risk of aortic aneurym and aortic dissection with use of these popular antibiotics.  The manufacturers of Levaquin, Avelox, Cipro, Noroxin, Floxin and Factive have not disclosed this increased risk.

FQAD is not a single side effect that comes from the use of an effective drug used in a life threatening injury. FQAD is a serious life changing disability that can cause permanent damage to previously health individuals in multiple body systems. FQAD often occurs after FQs were prescribed for use in treatment of illnesses that would have resolved on their own without the use of an antibiotic.

There is a lack of information about the multi-symptom problems that occur in FQAD.   Injured individuals report that even specialists and doctors were unaware of the possibility that specific reported side effects could be the progression of a disability that was triggered through FQ treatment. The connection is often not made because some of the FQAD symptoms do not appear until after the completion of the medication.

TruLaw does not believe that the manufacturers of these drugs properly warned of the risk of FQAD and the public needs to understand the risk of this serious disability.